Cellestia Biotech
Pioneering innovative therapeutics based on novel modes of action to treat autoimmune diseases and multi-drug resistant cancers.
Basel, Switzerland · Founded 2015 · $20.0M raised
- Headquarters
- Basel
- Employees
- 11–50
- Founded
- 2015
- Business Model
- B2B
- Website
- cellestia.com
- Total Funding
- $20.0M
- Last Round
- $20.0M Series ADec 2018
- Rounds
- 1
About
Cellestia Biotech is a clinical-stage biopharmaceutical company developing first-in-class therapeutics targeting the Notch signaling pathway for the treatment of multi-drug resistant cancers and autoimmune diseases. Its lead candidate CB-103, an oral pan-Notch inhibitor, has demonstrated safety and biological activity in Phase 1 trials and is advancing into Phase 2 for hematologic and solid tumor cancers, as well as proof-of-concept studies in graft-versus-host disease. Founded on pioneering academic research, Cellestia addresses cancers where conventional therapies fail by exploiting a novel mode of transcriptional inhibition distinct from prior Notch-targeting approaches.
Summary
Cellestia Biotech is a Biotech company based in Basel, Switzerland, founded in 2015. It has raised $20.0M in total across 1 round, most recently a $20.0M Series A round in Dec 2018.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Dec 2018
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Biopharmaceutical services company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...